Amylyx Pharmaceuticals, Inc. (AMLX)
|Net Income (ttm)||-184.02M|
|Day's Range||37.97 - 39.3|
|52-Week Range||6.51 - 39.78|
|Price Target||49.73 (+29.1%)|
|Earnings Date||Nov 10, 2022|
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. [Read more]
In 2021, AMLX's revenue was $285,000, a decrease of -56.15% compared to the previous year's $650,000. Losses were -$87.93 million, 108.0% more than in 2020.Financial Statements
According to 11 analysts, the average rating for AMLX stock is "Buy." The 12-month stock price forecast is 49.73, which is an increase of 29.10% from the latest price.
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Evercore ISI 5th Annual Hea...
The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.
Stocks moving after hours: Twitter, Amylyx Pharmaceuticals, AutoZone, Airbnb
Yahoo Finance Live's Seana Smith looks at several stocks trending in the after-hours trading session.
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the quarter ended September 30, 2022.
View the Nasdaq Opening Bell Ringing & CEO Message Here: LINK CAMBRIDGE, Mass. , Oct. 18, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the closing of its previously announced upsized underwritten public offering of 7,697,812 shares of its common ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces Launch of Public Offering.
Amylyx Pharmaceuticals Inc.'s AMLX, -1.13% new treatment for amyotrophic lateral sclerosis just received approval in the U.S., but it's already facing questions about effectiveness and price.
Amylyx (AMLX) obtains the FDA's approval for its oral, fixed-dose combination therapy for treating adults with amyotrophic lateral sclerosis (ALS) after a few roadblocks.
Relvyrio, Amylyx's drug to treat ALS, a neurological disorder without a cure, was approved even though the treatment is very expensive.
Shares of Amylyx Pharmaceuticals (NASDAQ: AMLX ) stock were up as much as 10% in premarket trading today on news that the U.S. Food and Drug Administration (FDA) has approved its treatment of the deadly...
Amylyx Pharmaceuticals Inc said on Friday it has set the list price of its newly approved drug to slow the progression of amyotrophic lateral sclerosis (ALS) at about $158,000 per year in the United Sta...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS in Adults.
After a long road, Amylyx Pharmaceuticals won FDA approval for its ALS treatment late Thursday, leading AMLX stock to surge. The post IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Lon...
The drug is the first that the Food and Drug Administration has approved for ALS, also known as Lou Gehrig's disease, in five years.
WASHINGTON — A much-debated drug for Lou Gehrig's disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government re...
The U.S. Food and Drug Administration on Thursday approved Amylyx Pharmaceuticals Inc's drug for slowing progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death.
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx announced that the donated clinical data from the placebo arm of the CENTAUR clinical trial are now available in the PRO-ACT database.
The experimental treatment was recently backed by an FDA advisory committee
Amylyx Pharmaceuticals has just one drug in its pipeline -- but it's for ALS, and the available treatments for that disease leave much to be desired.
Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Comp...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals today announced the publication of preclinical data.
The FDA will most likely approve this company's first drug, but what comes next is more difficult to predict.